Sunshine Biopharma Inc. (SBFM)

↓ Download CSV

CIK 0001402328 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated CO
  • Fiscal year ends Dec 31

In fiscal 2025, Sunshine Biopharma Inc. reported revenue of $36.31M, up 4.1% from the prior year. The company ran a net loss, with a net margin of -16.5% and a gross margin of 33.8%. It held $30.08M in total assets against $7.04M in total liabilities.

Key ratios (FY2025)

33.8%
Gross margin
-17.2%
Operating margin
-16.5%
Net margin
-25.9%
Return on equity
+4.1%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$36.31M$34.87M$24.09M$4.35M$228.4K$71.4K$21.1K$0$0
Cost of Revenue$24.05M$24.20M$15.75M$2.65M$117.8K$25.8K$11.1K$0$0
Gross Profit$12.26M$10.67M$8.34M$1.70M$110.6K$45.6K$10.1K$0$0
Operating Income-$6.23M-$5.81M-$4.79M-$27.00M-$2.44M-$576.9K-$641.6K-$1.16M-$857.2K-$993.1K
Net Income-$5.98M-$5.13M-$4.51M-$26.74M-$12.44M-$2.78M-$1.66M-$2.16M-$1.04M-$3.50M
EPS (Diluted)$-1.44$-7.32$-351.36$-1.76$-4.76$-2.73$-0.15$-0.71$-0.02$-0.01
Total Assets$30.08M$30.56M$27.35M$29.24M$2.20M$1.05M$98.1K$1.15M$257.5K$64.4K
Total Liabilities$7.04M$7.06M$6.14M$7.62M$1.99M$2.00M$833.5K$1.20M$830.8K$274.1K
Shareholders' Equity$23.04M$23.50M$21.21M$21.63M$211.7K-$954.8K-$735.4K-$55.8K-$573.4K-$209.7K
Cash & Equivalents$21.83M$2.05M$989.9K$40.5K$110.5K$107.5K$57.5K
Operating Cash Flow-$5.33M-$12.52M-$8.78M-$5.25M-$1.83M-$657.3K-$495.8K-$512.8K-$543.5K-$314.2K
Capital Expenditures$174.5K$1.66M$82.3K$194.0K$0$1.2K$860$18.9K$3.7K$3.4K
Shares Outstanding4.91M2.58M14.0K22.59M2.59M1.73M35.32M4.28M45.94M769.40M